|Dear friends and supporters,
Psychedelic Science 2017 was truly amazing. Thank you to everyone who attended or helped make possible the largest psychedelic conference in history, with over 3,000 people from 40+ countries coming together for a whirlwind six days of learning, discovery, exploration, and community-building. The New York Times called it “America’s premiere psychedelics conference”; New York Magazine called it “the psychedelics state of the union.” Plus, there’s always more to explore— over 100 videos are now available online free!
After such an inspiring gathering, we are even more motivated and working with the U.S. Food and Drug Administration to launch the first MAPS-sponsored Phase 3 trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD)—with over a dozen sites across North America and Israel. In addition to protocol discussions with the FDA, we are continuing to prepare researchers through our MDMA Therapy Training Program and our recent Investigator’s Meeting at Psychedelic Science 2017.
The Zendo Project is getting ready for a busy summer providing psychedelic harm reduction at festivals. Stay tuned for our upcoming crowdfunding campaign to learn how you can help the Zendo Project keep festival attendees safer this season.
In the May 2017 edition of the MAPS Email Newsletter, you’ll also learn:
- MAPS receives a response from the FDA as part of the Special Protocol Assessment (SPA) for our Phase 3 trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD)
- The first pair of participants completes their six-month follow-up interview in our ongoing study of MDMA and Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD
- Three more participants receive marijuana in our ongoing clinical trial of smoked marijuana for PTSD in U.S. veterans
- Our MDMA therapy training study enrolls two more participants
Join the momentum — connect with MAPS on Facebook, Twitter, YouTube, reddit, Tumblr, Pinterest, Google+, LinkedIn, and Instagram.